A simple and reproducible method for the determination of clospipramine in plasma by HPLC has been developed. Sample preparation and procedures for HPLC were as follows; 1-heptane containing 1.5% isopentyl alcohol (n-HIAA) was added to alkalized plasma using 5-[3-(2-oxo-1, 2, 3, 5, 6, 7, 8, 8a-octahydroimidazo [1, 2-a] pyridine-3-spiro-4'-piperidino)propyl]-10, 11-dihydro-5
H-dibenzo[
b,
f] azapine) (Y-15364) as an internal standard. After shaking and centrifugation of the sample, the aqueous phase was frozen in a dry ice-2-propanol mixture. The organic phase was transferred to another tube. Drugs were extracted with dilute hydrochloric acid. This acidic solution was frozen in a dry ice-2-propanol mixture; and the organic phase was discarded. The acidic solution was made alkaline, then extracted with
n-HIAA, and again frozen in a dry ice-2-propanol mixture. The organic phase was transferred to another tube and dried under a stream of N
2. The residue was dissolved in 30μl of 38% acetonitrile solution. Twentyfive microliters of the solution were injected into the chromatograph which was equipped with a system Model 510, U6K injector, μ Bondasphere 5 phenyl-100Å column (3.9mm×15cm), and Model 481 UV detector setting at 254nm (Nihon Waters Ltd.). The flow rate of the mobile phase {38% acetonitrile containing 10mM dibutylamine phosphate (pH 3.0)} was 0.7ml/min. The retention times for Y-15364 and clospipramine were 6.0 and 8.5min, respectively. The limit of detection was 1.0ng/ml for clospipramine in plasma. Within-run reproducibility datum for 50ng/ml is 3.5% (
n=7). The result of the measurement of the clospipramine concentration in plasma after a single oral administration to schizophrenic patients, indicates that the proposed method would be applicable in clinical treatment of antipsychcotic drugs.
View full abstract